Latest action: Referred to the House Committee on Energy and Commerce.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Removes legal protections for vaccine manufacturers from lawsuits.
The problem
Vaccine manufacturers have limited liability protections. Some believe this carveout unfairly shields companies from accountability for vaccine-related injuries.
The proposal
The bill eliminates legal immunities that currently protect vaccine makers from certain lawsuits related to vaccine safety and injuries.
The impact
Vaccine manufacturers face increased lawsuit liability. Vaccine development costs may rise. Injured parties gain more legal options. Public health programs could be affected.
Vaccine manufacturers would face more legal responsibility for product safety. This could incentivize stricter quality controls and safety measures. Injured individuals would have clearer pathways to seek compensation.
People who believe they were harmed by vaccines could sue manufacturers directly instead of relying on limited government compensation programs. This expands access to justice for potential vaccine injury claimants.
Removing liability protections could encourage companies to invest more in vaccine safety research and monitoring. Market competition and liability concerns might drive innovation in safer vaccine development.
Higher liability costs could discourage companies from developing vaccines, especially for rare diseases or new outbreaks. Smaller pharmaceutical companies might exit the vaccine market entirely. This could reduce vaccine availability.
Higher liability insurance and legal costs would likely be passed to consumers and government programs. Vaccine prices could rise significantly, making them less affordable and accessible.
Litigation risks could slow emergency vaccine deployment during disease outbreaks. Manufacturers might avoid producing vaccines for pandemic scenarios. Public health response capabilities could be weakened.
Without liability protections, companies could face numerous lawsuits regardless of merit. Legal costs would increase even for baseless claims. Resources would be diverted from actual safety improvements.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.